Propeller Health updated logoPropeller Health announced that it received FDA 510(k) clearance for connecting patients using its Symbicort Inhaler to its digital health platform.

The Madison, Wis.-based company’s digital health platform already connects to inhalers used by asthma and COPD patients, including ones manufactured by Boehringer Ingelheim, GlaxoSmithKline, Novartis and Orion, along with other generic equivalents.

Propeller’s digital health platform helps users with asthma or COPD manage their condition in tandem with their clinician by attaching sensors to existing inhalers to deliver insights on medication use to the Propeller app on their smartphone. Then, users can share insights with their clinician to help inform their treatment plan.

Clinical studies have revealed that the Propeller platform can increase asthma control by up to 63 percent, increase medication adherence by up to 58 percent, reduce asthma-related emergency department visits and hospitalizations by as much as 57 percent and reduce COPD-related healthcare utilization by as much as 35 percent.

“Our partnership with AstraZeneca will give respiratory patients a tool to help manage their condition and increase their medication adherence, a critical factor in keeping people out of the hospital,” Propeller Health co-founder & CEO David Van Sickle said in a news release. “This is an important step in transforming the way people receive preventative care, enabling self-management from home and ensuring that providers have the bandwidth to focus on high-risk patients.”